Trevi Therapeutics (TRVI) Accumulated Expenses (2018 - 2026)

Trevi Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 75.3% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 75.3% YoY), while the FY2025 annual figure was $5.5 million, down 18.78% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.3 million, down from $5.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $6.8 million in Q4 2024, with the low at $618000.0 in Q1 2023.
• The 5-year median for Accumulated Expenses is $3.6 million (2023), against an average of $3.4 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 723.99% in 2022, then sank 84.08% in 2023.
• Trevi Therapeutics' Accumulated Expenses stood at $1.5 million in 2022, then soared by 145.95% to $3.7 million in 2023, then jumped by 83.61% to $6.8 million in 2024, then retreated by 18.78% to $5.5 million in 2025, then slumped by 76.91% to $1.3 million in 2026.
• Business Quant data shows TRVI's Accumulated Expenses at $1.3 million in Q1 2026, $5.5 million in Q4 2025, and $2.4 million in Q3 2025.